LONGEVITY AS A SERVICE

Alex Zhavoronkov, PhD in InsilicoMedicine

Sep 9, 2019

Insilico Medicine Secures $37M in Series B Funding Led by Qiming Venture Partners

Original press release by Qiming Venture Partners

Tuesday, September 10, Hong Kong — Insilico Medicine, a pioneer in next-generation artificial intelligence…

Alex Zhavoronkov, PhD in InsilicoMedicine

Feb 8, 2019

Insilico to contribute to Oxford CDT research and educational program in AI

Alex Zhavoronkov, PhD in InsilicoMedicine

Jan 16, 2019

I would like to congratulate our investors, friends, business partners, and fellow longevity biotechnology experts at Juvenescence on the first close of their series B. The company…

Alex Zhavoronkov, PhD in InsilicoMedicine

Jan 10, 2019

Two longevity biotechnology companies partner to discover drugs that target aging

Alex Zhavoronkov, PhD in InsilicoMedicine

Jan 7, 2019

TARA Biosystems and Insilico Medicine announce collaboration for cardiac disease

Alex Zhavoronkov, PhD in InsilicoMedicine

Dec 1, 2018

Molecular Sets (MOSES): a collaborative benchmarking platform for generative drug discovery

1 response

Alex Zhavoronkov, PhD in InsilicoMedicine

Aug 27, 2018

$100 million+ in “biobucks” for AI-powered drug discovery and longevity research: Q&A

1 response

Alex Zhavoronkov, PhD in InsilicoMedicine

Aug 14, 2018

バック研究所(The Buck Institute)、インシリコ(Insilico) 医学、およびジュベネッセンス(Juvenescence)は老化関連疾患を阻害する治療薬を開発するためにナパセラピューティクスを設立する。コラボレーションにより老化関連ターゲットを標的にしたAI技術を応用する。

Alex Zhebrak in InsilicoMedicine

Jul 26, 2018

Insilico Medicine at ICML 2018 recap

Earlier this month our team attended the thirty-fifth annual International Conference on…

Ivan Ozerov in InsilicoMedicine

Jul 19, 2018

Insilico Medicine makes a big move to solve Duchenne Muscular Dystrophy

My beloved company Insilico Medicine, Inc. today announced a research collaboration with computationally-driven biopharmaceutical company A2A Pharmaceuticals to develop novel small molecules for Duchenne…

1 response

About

InsilicoMedicine

Insilico Medicine is an artificial intelligence company focusing on drug discovery, biomarker development, digital medicine and aging research. It is developing a full-stack engine and naturally plug-and-play into the "Big Pharma", "Big Tech" and consumer companies.

More information

Followers

392

Elsewhere